MX2015004460A - Metodos para el tratamiento del sindrome de alport. - Google Patents
Metodos para el tratamiento del sindrome de alport.Info
- Publication number
- MX2015004460A MX2015004460A MX2015004460A MX2015004460A MX2015004460A MX 2015004460 A MX2015004460 A MX 2015004460A MX 2015004460 A MX2015004460 A MX 2015004460A MX 2015004460 A MX2015004460 A MX 2015004460A MX 2015004460 A MX2015004460 A MX 2015004460A
- Authority
- MX
- Mexico
- Prior art keywords
- alport syndrome
- mir
- treatment
- methods
- certain embodiments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
Abstract
Se proporcionan en la presente métodos para el tratamiento del Síndrome de Alport, usando oligonucleótidos modificados dirigidos a miR-21. En ciertas realizaciones, un oligonucleótido modificado dirigido a miR-21 mejora la función renal y/o reduce la fibrosis en sujetos que tienen Síndrome de Alport. En ciertas realizaciones, la administración de un oligonucleótido modificado dirigido a miR-21 retrasa el inicio de la enfermedad renal de etapa terminal en un sujeto que tiene Síndrome de Alport. En ciertas realizaciones, un oligonucleótido modificado dirigido a miR-21 retrasa la necesidad de diálisis o trasplante de riñón en un sujeto que tiene Síndrome de Alport.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711514P | 2012-10-09 | 2012-10-09 | |
| US201361779137P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/063884 WO2014058881A1 (en) | 2012-10-09 | 2013-10-08 | Methods for treatment of alport syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015004460A true MX2015004460A (es) | 2015-11-23 |
| MX356340B MX356340B (es) | 2018-05-23 |
Family
ID=49382663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004460A MX356340B (es) | 2012-10-09 | 2013-10-08 | Oligonucleótidos para usarse en el tratamiento del síndrome de alport. |
Country Status (35)
| Country | Link |
|---|---|
| US (7) | US9012423B2 (es) |
| EP (2) | EP2906698B1 (es) |
| JP (4) | JP6272880B2 (es) |
| KR (4) | KR20230136686A (es) |
| CN (1) | CN104718295B (es) |
| AR (1) | AR092940A1 (es) |
| AU (3) | AU2013329427B2 (es) |
| BR (1) | BR112015007709B1 (es) |
| CA (1) | CA2885605A1 (es) |
| CL (1) | CL2015000873A1 (es) |
| CR (1) | CR20150236A (es) |
| CY (1) | CY1122479T1 (es) |
| DK (1) | DK2906698T3 (es) |
| EA (1) | EA201590711A1 (es) |
| ES (2) | ES2753174T3 (es) |
| HK (1) | HK1212378A1 (es) |
| HR (1) | HRP20191948T1 (es) |
| HU (1) | HUE045858T2 (es) |
| IL (2) | IL237768B (es) |
| LT (1) | LT2906698T (es) |
| MX (1) | MX356340B (es) |
| MY (1) | MY183921A (es) |
| NZ (1) | NZ630596A (es) |
| PH (1) | PH12015500781B1 (es) |
| PL (1) | PL2906698T3 (es) |
| PT (1) | PT2906698T (es) |
| RS (1) | RS60014B1 (es) |
| SG (1) | SG11201502748RA (es) |
| SI (1) | SI2906698T1 (es) |
| TN (1) | TN2015000099A1 (es) |
| TW (1) | TWI641388B (es) |
| UA (1) | UA116639C2 (es) |
| UY (1) | UY35069A (es) |
| WO (1) | WO2014058881A1 (es) |
| ZA (1) | ZA201502087B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2281887A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| HUE054129T2 (hu) | 2011-04-25 | 2021-08-30 | Sanofi Sa | Mikro-RNS vegyületek és eljárások miR-21 aktivitás modulálására |
| SG11201406931XA (en) | 2012-04-25 | 2014-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| WO2015061536A1 (en) | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CA2955481A1 (en) * | 2014-07-25 | 2016-01-28 | Goldfinch Biopharma, Inc. | Collagen iv replacement |
| US10744178B2 (en) | 2014-08-21 | 2020-08-18 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of disease |
| CA2963288A1 (en) | 2014-10-03 | 2016-04-07 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2017060731A1 (en) | 2015-10-09 | 2017-04-13 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| EP3390636B1 (en) | 2015-12-14 | 2021-05-19 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of dravet syndrome |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| JP6633812B2 (ja) | 2016-11-08 | 2020-01-22 | リアタ ファーマシューティカルズ インコーポレイテッド | バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法 |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| KR20190100225A (ko) * | 2016-12-28 | 2019-08-28 | 다이이찌 산쿄 가부시키가이샤 | 알포트 증후군 치료약 |
| JP2020518633A (ja) * | 2017-05-04 | 2020-06-25 | サノフイＳａｎｏｆｉ | アルポート症候群を治療するための方法 |
| CN110945125A (zh) | 2017-06-06 | 2020-03-31 | 齐默尔根公司 | 用于改进大肠杆菌的htp基因工程改造平台 |
| CA3061984A1 (en) | 2017-06-06 | 2018-12-13 | Zymergen Inc. | A htp genomic engineering platform for improving fungal strains |
| PT3673080T (pt) | 2017-08-25 | 2023-12-06 | Stoke Therapeutics Inc | Oligómeros anti-sentido para o tratamento de estados patológicos e outras doenças |
| AU2018355237A1 (en) * | 2017-10-23 | 2020-05-21 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| US11066663B2 (en) | 2018-10-31 | 2021-07-20 | Zymergen Inc. | Multiplexed deterministic assembly of DNA libraries |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| JP2022524043A (ja) | 2019-03-08 | 2022-04-27 | ザイマージェン インコーポレイテッド | 微生物の反復ゲノム編集 |
| IL298063A (en) | 2020-05-11 | 2023-01-01 | Stoke Therapeutics Inc | opa1 antisense oligomers for the treatment of conditions and diseases |
| WO2023217764A1 (en) * | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE359804T1 (de) * | 1998-05-22 | 2007-05-15 | Boys Town Nat Res Hospital | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten |
| KR100574597B1 (ko) * | 1998-05-22 | 2006-04-28 | 보이스 타운 내셔널 리서치 호스피탈 | α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도 |
| US20060008817A1 (en) | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| EP2428571B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| ITMI20032528A1 (it) * | 2003-12-19 | 2005-06-20 | Francesco Santangelo | Uso di cistina o di cisteina per la prevenzione e il |
| US7585550B2 (en) | 2004-02-02 | 2009-09-08 | College Of William And Mary | Process for modifying polymeric surfaces using deep UV irradiation |
| EP2474616B1 (en) | 2004-05-28 | 2015-07-08 | Asuragen, Inc. | Methods and compositions involving microRNA |
| CA2576233C (en) | 2004-08-10 | 2016-03-15 | Alnylam Pharmaceuticals, Inc. | Conjugate comprising an antagomir and a ligand |
| EP1802331A2 (en) | 2004-09-08 | 2007-07-04 | Boys Town National Research Hospital | Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12 |
| EP2281887A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| WO2006069584A2 (en) | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
| US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
| EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| EP3431602A1 (en) | 2006-04-03 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| CA2649045C (en) | 2006-04-03 | 2019-06-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| KR101129509B1 (ko) | 2006-10-03 | 2012-04-13 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 함유 조성물 |
| EP2476762B1 (de) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen |
| CA2671294A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| EP2118118B1 (en) | 2007-01-19 | 2017-09-27 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
| WO2008151631A2 (en) | 2007-06-15 | 2008-12-18 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| US20080317725A1 (en) * | 2007-06-20 | 2008-12-25 | Baum Seth J | Compositions and methods of treating chronic kidney disease |
| US8440637B2 (en) | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
| WO2009058907A2 (en) | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
| WO2009091972A2 (en) | 2008-01-18 | 2009-07-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
| CA2714120A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| US8361980B2 (en) | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
| CN102549166A (zh) | 2009-02-26 | 2012-07-04 | 俄亥俄州立大学研究基金会 | 从未吸烟者中的MicroRNA及相关材料和方法 |
| EP2440566A4 (en) | 2009-06-08 | 2013-10-16 | Miragen Therapeutics | CHEMICAL MODIFICATION RULES FOR INHIBITORS AND MIMETICS OF MIRIK |
| WO2011126842A2 (en) | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
| HUE054129T2 (hu) | 2011-04-25 | 2021-08-30 | Sanofi Sa | Mikro-RNS vegyületek és eljárások miR-21 aktivitás modulálására |
| WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| SG11201406931XA (en) | 2012-04-25 | 2014-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| AU2013278011B2 (en) | 2012-06-21 | 2018-09-20 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| WO2014048441A1 (en) | 2012-09-26 | 2014-04-03 | Mirrx Therapeutics | Oligomers with improved off-target profile |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2013
- 2013-08-10 UA UAA201504453A patent/UA116639C2/uk unknown
- 2013-10-08 UY UY35069A patent/UY35069A/es not_active Application Discontinuation
- 2013-10-08 MY MYPI2015000876A patent/MY183921A/en unknown
- 2013-10-08 KR KR1020237031594A patent/KR20230136686A/ko active Application Filing
- 2013-10-08 EP EP13777458.4A patent/EP2906698B1/en active Active
- 2013-10-08 CA CA2885605A patent/CA2885605A1/en active Pending
- 2013-10-08 TW TW102136388A patent/TWI641388B/zh active
- 2013-10-08 JP JP2015535891A patent/JP6272880B2/ja active Active
- 2013-10-08 ES ES13777458T patent/ES2753174T3/es active Active
- 2013-10-08 LT LT13777458T patent/LT2906698T/lt unknown
- 2013-10-08 ES ES19188663T patent/ES2960488T3/es active Active
- 2013-10-08 KR KR1020157009045A patent/KR102165189B1/ko active IP Right Grant
- 2013-10-08 CN CN201380051249.9A patent/CN104718295B/zh active Active
- 2013-10-08 PL PL13777458T patent/PL2906698T3/pl unknown
- 2013-10-08 SI SI201331597T patent/SI2906698T1/sl unknown
- 2013-10-08 KR KR1020207028577A patent/KR102349184B1/ko active IP Right Grant
- 2013-10-08 BR BR112015007709-9A patent/BR112015007709B1/pt active IP Right Grant
- 2013-10-08 PT PT137774584T patent/PT2906698T/pt unknown
- 2013-10-08 EA EA201590711A patent/EA201590711A1/ru unknown
- 2013-10-08 RS RS20191380A patent/RS60014B1/sr unknown
- 2013-10-08 WO PCT/US2013/063884 patent/WO2014058881A1/en active Application Filing
- 2013-10-08 EP EP19188663.9A patent/EP3620522B1/en active Active
- 2013-10-08 US US14/048,827 patent/US9012423B2/en active Active
- 2013-10-08 AR ARP130103643A patent/AR092940A1/es not_active Application Discontinuation
- 2013-10-08 SG SG11201502748RA patent/SG11201502748RA/en unknown
- 2013-10-08 AU AU2013329427A patent/AU2013329427B2/en active Active
- 2013-10-08 MX MX2015004460A patent/MX356340B/es active IP Right Grant
- 2013-10-08 DK DK13777458T patent/DK2906698T3/da active
- 2013-10-08 NZ NZ630596A patent/NZ630596A/en unknown
- 2013-10-08 KR KR1020227000173A patent/KR20220005634A/ko not_active Application Discontinuation
- 2013-10-08 HU HUE13777458A patent/HUE045858T2/hu unknown
-
2015
- 2015-03-16 TN TNP2015000099A patent/TN2015000099A1/fr unknown
- 2015-03-16 IL IL237768A patent/IL237768B/en active IP Right Grant
- 2015-03-26 ZA ZA2015/02087A patent/ZA201502087B/en unknown
- 2015-04-02 US US14/677,387 patent/US9359609B2/en active Active
- 2015-04-07 CL CL2015000873A patent/CL2015000873A1/es unknown
- 2015-04-08 PH PH12015500781A patent/PH12015500781B1/en unknown
- 2015-05-07 CR CR20150236A patent/CR20150236A/es unknown
-
2016
- 2016-01-06 HK HK16100081.2A patent/HK1212378A1/xx unknown
- 2016-05-10 US US15/151,290 patent/US9688986B2/en active Active
-
2017
- 2017-05-26 US US15/606,554 patent/US9970011B2/en active Active
- 2017-12-28 JP JP2017253345A patent/JP2018080190A/ja active Pending
-
2018
- 2018-04-09 US US15/948,450 patent/US20180298385A1/en not_active Abandoned
- 2018-10-08 IL IL262200A patent/IL262200A/en unknown
-
2019
- 2019-07-29 AU AU2019210494A patent/AU2019210494A1/en not_active Abandoned
- 2019-10-16 JP JP2019189071A patent/JP2020073479A/ja active Pending
- 2019-10-28 HR HRP20191948TT patent/HRP20191948T1/hr unknown
- 2019-10-30 CY CY20191101129T patent/CY1122479T1/el unknown
-
2020
- 2020-01-21 US US16/747,837 patent/US20200283765A1/en not_active Abandoned
-
2021
- 2021-07-02 US US17/366,796 patent/US20220098582A1/en not_active Abandoned
- 2021-11-18 AU AU2021269404A patent/AU2021269404A1/en active Pending
-
2022
- 2022-05-23 JP JP2022083586A patent/JP2022110140A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500781B1 (en) | Methods for treatment of alport syndrome | |
| ZA201501541B (en) | Supported catalyst and active form thereof, and preparation method and use thereof | |
| CL2013003341A1 (es) | Un metodo y sistema para autenticar una sesion de un usuario. | |
| RS20140202A1 (en) | BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17 | |
| EA201391585A1 (ru) | Терапевтические нуклеазные композиции и способы | |
| BRPI1010718A2 (pt) | sistemas modelo e regimes de tratamento para tratar doença neurológica. | |
| MX2014004862A (es) | Formulaciones de polimero acrilico. | |
| WO2009129387A3 (en) | Cationic lipids and uses thereof | |
| MX347620B (es) | Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica. | |
| MX2019013158A (es) | Metodos para el tratamiento del sindrome de alport. | |
| Havranek et al. | Low-cost telemedicine. | |
| AR128192A2 (es) | Métodos para el tratamiento del síndrome de alport | |
| AR119688A2 (es) | Métodos para el tratamiento del síndrome de alport | |
| MX2013012551A (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| CA142814S (en) | Medical patch | |
| 陈征宇 | Understanding DNA chains in confinement by using the wormlike-chain model | |
| Rakhmanova | Deutsche Syntax in Übungen und Aufgaben | |
| 卢希 | Creek Maze | |
| 이용성 et al. | KSBMB 2011 Congress | |
| Fu | Winner Takes All: A Belligerent Male Society——Discourse Strategies in Glengarry Glen Ross | |
| 周游 | What can you do? | |
| PAVAN | The Italian Market of Business Angels: Determinants of Performance | |
| 童国梁 | DESY/CERN | |
| Шапошникова | The organization of social work within the framework of socialization of modern youth | |
| 唐宇 | Happy New Year! |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |